drowsy < drug < druggable

Facettes : Author.f AffPays.f AffRegion.f AffVille.f AffOrg.f Mesh.f

List of bibliographic references

Number of relevant bibliographic references: 60.
[0-20] [0 - 20][0 - 50][20-40]

Ident.	Authors (with country if any)	Title
000029 (2020)	Yu-Shi Zhang [République populaire de Chine] ; Wei-Hong Cong [République populaire de Chine] ; Jing-Jing Zhang [République populaire de Chine] ; Fei-Fei Guo [République populaire de Chine] ; Hong-Mei Li [République populaire de Chine]	[Research progress of intervention of Chinese herbal medicine and its active components on human coronavirus].
000031 (2020)	J. Reina [Espagne]	[Remdesivir, the antiviral hope against SARS-CoV-2].
000032 (2020)	Ming Niu [République populaire de Chine] ; Rui-Lin Wang [République populaire de Chine] ; Zhong-Xia Wang [République populaire de Chine] ; Ping Zhang [République populaire de Chine] ; Zhao-Fang Bai [République populaire de Chine] ; Jing Jing [République populaire de Chine] ; Yu-Ming Guo [République populaire de Chine] ; Xu Zhao [République populaire de Chine] ; Xiao-Yan Zhan [République populaire de Chine] ; Zi-Teng Zhang [République populaire de Chine] ; Xue-Ai Song [République populaire de Chine] ; En-Qiang Qin [République populaire de Chine] ; Jia-Bo Wang [République populaire de Chine] ; Xiao-He Xiao [République populaire de Chine]	[Rapid establishment of traditional Chinese medicine prevention and treatment of 2019-nCoV based on clinical experience and molecular docking].
000100 (2020)	Chang-Quan Ling	Traditional Chinese medicine is a resource for drug discovery against 2019 novel coronavirus (SARS-CoV-2)
000104 (2020)	Sean Ekins [États-Unis] ; Thomas R. Lane [États-Unis] ; Peter B. Madrid [États-Unis]	Tilorone: a Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond.
000139 (2020)	Jin-Yan Li [République populaire de Chine] ; Zhi You [République populaire de Chine] ; Qiong Wang [République populaire de Chine] ; Zhi-Jian Zhou [République populaire de Chine] ; Ye Qiu [République populaire de Chine] ; Rui Luo [République populaire de Chine] ; Xing-Yi Ge [République populaire de Chine]	The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future.
000149 (2020)	Y J Duan [République populaire de Chine] ; Q. Liu [République populaire de Chine] ; S Q Zhao [République populaire de Chine] ; F. Huang [République populaire de Chine] ; L. Ren [République populaire de Chine] ; L. Liu [République populaire de Chine] ; Y W Zhou [République populaire de Chine]	The Trial of Chloroquine in the Treatment of Corona Virus Disease 2019 （COVID-19） and Its Research Progress in Forensic Toxicology.
000167 (2020)	Leon Caly [Australie] ; Julian D. Druce [Australie] ; Mike G. Catton [Australie] ; David A. Jans [Australie] ; Kylie M. Wagstaff [Australie]	The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
000183 (2020)	Sophie Alexandra Baron [France] ; Christian Devaux [France] ; Philippe Colson [France] ; Didier Raoult [France] ; Jean-Marc Rolain [France]	Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?
000185 (2020)	Rameez Jabeer Khan [Inde] ; Rajat Kumar Jha [Inde] ; Gizachew Muluneh Amera [Inde] ; Monika Jain [Inde] ; Ekampreet Singh [Inde] ; Amita Pathak [Inde] ; Rashmi Prabha Singh [Inde] ; Jayaraman Muthukumaran [Inde] ; Amit Kumar Singh [Inde]	Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2'-O-ribose methyltransferase.
000186 (2020)	Jiayu Liao [États-Unis] ; George Way [États-Unis] ; Vipul Madahar [États-Unis]	Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenzas virus therapies.
000205 (2020)	Jacques Fantini [France] ; Coralie Di Scala [France] ; Henri Chahinian [France] ; Nouara Yahi [France]	Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection.
000251 (2020)	Shu-Ren Li [République populaire de Chine] ; Zi-Jian Tang [République populaire de Chine] ; Zai-Han Li [République populaire de Chine] ; Xuan Liu [République populaire de Chine]	Searching therapeutic strategy of new coronavirus pneumonia from angiotensin-converting enzyme 2: the target of COVID-19 and SARS-CoV.
000286 (2020)	Michele Costanzo ; Maria Anna Rachele De Giglio ; Giovanni Nicola Roviello	SARS CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus.
000300 (2020)	Ashley Barlow [États-Unis] ; Kaitlin M. Landolf [États-Unis] ; Brooke Barlow [États-Unis] ; Siu Yan Amy Yeung [États-Unis] ; Jason J. Heavner [États-Unis] ; Cassidy W. Claassen [Zambie] ; Mojdeh S. Heavner [États-Unis]	Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.
000315 (2020)	Yu-Chen Cao [République populaire de Chine] ; Qi-Xin Deng [République populaire de Chine] ; Shi-Xue Dai [République populaire de Chine]	Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence
000317 (2020)	Ashleigh Shannon [France] ; Nhung Thi Tuyet Le [France] ; Barbara Selisko [France] ; Cecilia Eydoux [France] ; Karine Alvarez [France] ; Jean-Claude Guillemot [France] ; Etienne Decroly [France] ; Olve Peersen [États-Unis, France] ; Francois Ferron [France] ; Bruno Canard [France]	Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites
000330 (2020)	Tarek Mohamed Abd El-Aziz [États-Unis, Égypte] ; James D. Stockand [États-Unis]	Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status
000383 (2020)	Bo Ram Beck [Corée du Sud] ; Bonggun Shin [Corée du Sud, États-Unis] ; Yoonjung Choi [Corée du Sud] ; Sungsoo Park [Corée du Sud] ; Keunsoo Kang [Corée du Sud]	Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model
000396 (2020)	Junxiong Pang [Singapour] ; Min Xian Wang [Singapour] ; Ian Yi Han Ang ; Sharon Hui Xuan Tan ; Ruth Frances Lewis ; Jacinta I-Pei Chen ; Ramona A. Gutierrez ; Sylvia Xiao Wei Gwee [Singapour] ; Pearleen Ee Yong Chua [Singapour] ; Qian Yang ; Xian Yi Ng ; Rowena K. S. Yap ; Hao Yi Tan ; Yik Ying Teo ; Chorh Chuan Tan ; Alex R. Cook ; Jason Chin-Huat Yap ; Li Yang Hsu	Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review
000415 (2020)	Laure Elens [Belgique] ; Loralie J. Langman [États-Unis] ; Dennis A. Hesselink [Pays-Bas] ; Stein Bergan [Norvège] ; Dirk Jan A R. Moes [Pays-Bas] ; Mariadelfina Molinaro [Italie] ; Raman Venkataramanan [États-Unis] ; Florian Lemaitre [France]	Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/2020/Analysis

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i -k "drug" 

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i  \
                -Sk "drug" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    2020
   |étape=   Analysis
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    drug
}}

---

This area was generated with Dilib version V0.6.33. Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021